Nakabayashi M - Search Results

1

Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer.

Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Nakabayashi M, et al. Cancer. 2006 Sep 1;107(5):975-81. doi: 10.1002/cncr.22085. Cancer. 2006. PMID: 16862573 Free article.

2

Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.

McKay RR, Werner L, Fiorillo M, Nakabayashi M, Kantoff PW, Taplin ME. McKay RR, et al. Among authors: nakabayashi m. Prostate Cancer Prostatic Dis. 2016 Dec;19(4):398-405. doi: 10.1038/pcan.2016.31. Epub 2016 Aug 9. Prostate Cancer Prostatic Dis. 2016. PMID: 27502737 Free PMC article.

3

Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer.

Nakabayashi M, Oh WK. Nakabayashi M, et al. Curr Treat Options Oncol. 2004 Oct;5(5):349-55. doi: 10.1007/s11864-004-0025-3. Curr Treat Options Oncol. 2004. PMID: 15341673 Review.

4

Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.

Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK. Nakabayashi M, et al. BJU Int. 2005 Oct;96(6):783-6. doi: 10.1111/j.1464-410X.2005.05714.x. BJU Int. 2005. PMID: 16153200

5

Chemotherapy for high-risk localized prostate cancer.

Nakabayashi M, Oh WK. Nakabayashi M, et al. BJU Int. 2006 Apr;97(4):679-83. doi: 10.1111/j.1464-410X.2006.06092.x. BJU Int. 2006. PMID: 16536752 Review. No abstract available.

6

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.

Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS. Oh WK, et al. Among authors: nakabayashi m. Cancer. 2007 Mar 15;109(6):1090-6. doi: 10.1002/cncr.22504. Cancer. 2007. PMID: 17311345 Free article.

7

Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.

Nakabayashi M, Ling J, Xie W, Regan MM, Oh WK. Nakabayashi M, et al. Cancer J. 2007 Mar-Apr;13(2):125-9. doi: 10.1097/PPO.0b013e3180465940. Cancer J. 2007. PMID: 17476141

8

Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.

Xie W, Nakabayashi M, Regan MM, Oh WK. Xie W, et al. Among authors: nakabayashi m. Cancer. 2007 Dec 15;110(12):2709-15. doi: 10.1002/cncr.23111. Cancer. 2007. PMID: 17960608 Free article.

9

Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.

Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK. Nakabayashi M, et al. BJU Int. 2008 Feb;101(3):308-12. doi: 10.1111/j.1464-410X.2007.07331.x. BJU Int. 2008. PMID: 18184327

10

Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.

Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M. Ross RW, et al. Among authors: nakabayashi m. J Clin Oncol. 2008 Feb 20;26(6):842-7. doi: 10.1200/JCO.2007.13.6804. J Clin Oncol. 2008. PMID: 18281655

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

287 results

Search Page

Filters